IMM vs. TRX, COS, C4XD, DDDD, OKYO, SAR, AREC, AOR, POLB, and RLM
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include Tissue Regenix Group (TRX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), OKYO Pharma (OKYO), Sareum (SAR), Arecor Therapeutics (AREC), AorTech International (AOR), Poolbeg Pharma (POLB), and Realm Therapeutics (RLM). These companies are all part of the "biotechnology" industry.
ImmuPharma vs. Its Competitors
ImmuPharma (LON:IMM) and Tissue Regenix Group (LON:TRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.
17.4% of ImmuPharma shares are held by institutional investors. Comparatively, 37.0% of Tissue Regenix Group shares are held by institutional investors. 48.3% of ImmuPharma shares are held by insiders. Comparatively, 47.3% of Tissue Regenix Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Tissue Regenix Group has higher revenue and earnings than ImmuPharma. Tissue Regenix Group is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.
ImmuPharma has a net margin of 3,519.56% compared to Tissue Regenix Group's net margin of -3.46%. Tissue Regenix Group's return on equity of -2.87% beat ImmuPharma's return on equity.
In the previous week, ImmuPharma had 8 more articles in the media than Tissue Regenix Group. MarketBeat recorded 8 mentions for ImmuPharma and 0 mentions for Tissue Regenix Group. ImmuPharma's average media sentiment score of 0.21 beat Tissue Regenix Group's score of 0.00 indicating that ImmuPharma is being referred to more favorably in the media.
ImmuPharma has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Tissue Regenix Group has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.
Summary
Tissue Regenix Group beats ImmuPharma on 7 of the 13 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
This page (LON:IMM) was last updated on 7/27/2025 by MarketBeat.com Staff
Free IMM Stock Alerts